Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers. With a growing consensus that a new drug development model is needed, the question becomes what form should it take? Gain valuable insights to inform your market access strategy by:
- Learning what types of partnerships and funding will be key to the successful development of drugs for rare diseases going forward
- Hearing what impact the increased government funding announced in last fall’s federal budget is having on the pipeline of treatments
- Understanding what new routes to market and commercialization for these medications may be forged to get them to patients safely and expeditiously
Prepare your organization for a new market access model for treatments for rare diseases.